Skip to main content

15.09.2015 | Onkologie | Onlineartikel

Phase III results in local and regional lung cancer

The standard-of-care for inoperable stage III NSCLC is concurrent chemoradiotherapy. However, the role of consolidation chemotherapy remains controversial. The multi-targeted antifolate pemetrexed shows selective activity in non-squamous NSCLC. Choy et al. demonstrated that pemetrexed-platinum combinations can be administered at full systemic doses with concurrent thoracic radiotherapy (TRT) [1].

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten